Published in Mol Cancer on June 16, 2011
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med (2014) 0.91
Dissecting the genetics of the human transcriptome identifies novel trait-related trans-eQTLs and corroborates the regulatory relevance of non-protein coding loci†. Hum Mol Genet (2015) 0.86
Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biology. Adv Exp Med Biol (2014) 0.83
DNA damage-induced inhibition of rRNA synthesis by DNA-PK and PARP-1. Nucleic Acids Res (2013) 0.82
Effect and mechanism of poly (ADP-ribose) polymerase-1 in aldosterone-induced apoptosis. Mol Med Rep (2015) 0.80
Crystal Structure of Human SSRP1 Middle Domain Reveals a Role in DNA Binding. Sci Rep (2015) 0.77
Histone H4 expression is cooperatively maintained by IKKβ and Akt1 which attenuates cisplatin-induced apoptosis through the DNA-PK/RIP1/IAPs signaling cascade. Sci Rep (2017) 0.75
Histone displacement during nucleotide excision repair. Int J Mol Sci (2012) 0.75
Fine-Tuning of FACT by the Ubiquitin Proteasome System in Regulation of Transcriptional Elongation. Mol Cell Biol (2016) 0.75
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol (2000) 13.46
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Eukaryotic gene transcription with purified components. Methods Enzymol (1983) 9.71
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res (2004) 6.38
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell (1997) 5.92
The mechanism of human nonhomologous DNA end joining. J Biol Chem (2007) 5.02
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res (2008) 4.79
Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol (2003) 4.77
The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins. Nature (1999) 4.69
Immunoaffinity purification of mammalian protein complexes. Methods Enzymol (2003) 4.54
Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem (2005) 3.19
A means to a DNA end: the many roles of Ku. Nat Rev Mol Cell Biol (2004) 3.07
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
The life and death of DNA-PK. Oncogene (2005) 2.62
Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61
Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol (2001) 2.56
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem (1994) 2.36
The DNA-dependent protein kinase: the director at the end. Immunol Rev (2004) 2.20
DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res (2002) 2.13
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16. Mol Cell (2008) 1.99
Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res (2009) 1.87
Synthetic lethality--a new direction in cancer-drug development. N Engl J Med (2009) 1.84
DNA-PK is activated by nucleosomes and phosphorylates H2AX within the nucleosomes in an acetylation-dependent manner. Nucleic Acids Res (2003) 1.82
Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol (2005) 1.75
Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol (2008) 1.70
How do real tumors become resistant to cisplatin? Cell Cycle (2008) 1.60
The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev (2005) 1.36
Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res (2003) 1.34
The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proc Natl Acad Sci U S A (2000) 1.27
Drug resistance caused by reversion mutation. Cancer Res (2008) 1.23
Inhibition of homologous recombination by variants of the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs). Proc Natl Acad Sci U S A (2005) 1.23
DNA damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. EMBO J (2002) 1.21
Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem (2005) 1.18
Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol (2006) 1.12
Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin. J Biol Chem (2001) 1.10
Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. J Biol Chem (1996) 1.10
Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol (2000) 1.09
Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat (2004) 1.07
Vanillins--a novel family of DNA-PK inhibitors. Nucleic Acids Res (2003) 1.06
Radiation-induced DNA repair foci: spatio-temporal aspects of formation, application for assessment of radiosensitivity and biological dosimetry. Mutat Res (2010) 1.00
DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res (2009) 0.99
Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity. Gynecol Oncol (2007) 0.95
KU70/80, DNA-PKcs, and Artemis are essential for the rapid induction of apoptosis after massive DSB formation. Cell Signal (2008) 0.91
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature (2011) 9.30
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature (2012) 4.35
Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev (2006) 4.18
Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe (2012) 2.66
RAP80-directed tuning of BRCA1 homologous recombination function at ionizing radiation-induced nuclear foci. Genes Dev (2011) 2.00
Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. Anal Chem (2009) 1.65
Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci U S A (2011) 1.56
NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol Cell (2012) 1.44
PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol (2012) 1.30
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest (2014) 1.10
Online nanoflow RP-RP-MS reveals dynamics of multicomponent Ku complex in response to DNA damage. J Proteome Res (2010) 1.08
Online nanoflow multidimensional fractionation for high efficiency phosphopeptide analysis. Mol Cell Proteomics (2011) 1.02
DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res (2009) 0.99
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res (2008) 0.97
Fast kinase domain-containing protein 3 is a mitochondrial protein essential for cellular respiration. Biochem Biophys Res Commun (2010) 0.97
DNA ends alter the molecular composition and localization of Ku multicomponent complexes. Mol Cell Proteomics (2012) 0.96
Identification of FAM111A as an SV40 host range restriction and adenovirus helper factor. PLoS Pathog (2012) 0.95
Genome-scale proteome quantification by DEEP SEQ mass spectrometry. Nat Commun (2013) 0.94
PQBP1, a factor linked to intellectual disability, affects alternative splicing associated with neurite outgrowth. Genes Dev (2013) 0.89
Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol (2013) 0.89
DNA damage-induced inhibition of rRNA synthesis by DNA-PK and PARP-1. Nucleic Acids Res (2013) 0.82
Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol (2014) 0.81
An RS motif within the Epstein-Barr virus BLRF2 tegument protein is phosphorylated by SRPK2 and is important for viral replication. PLoS One (2013) 0.79
Protein complexes: the forest and the trees. Expert Rev Proteomics (2009) 0.78
Dephosphorylation of DBC1 by Protein Phosphatase 4 Is Important for p53-Mediated Cellular Functions. Mol Cells (2015) 0.75
Protected amine labels: a versatile molecular scaffold for multiplexed nominal mass and sub-Da isotopologue quantitative proteomic reagents. J Am Soc Mass Spectrom (2014) 0.75